Plaintiff
4 cases as plaintiff.
Company overview. Azurity Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company headquartered at 8 Cabot Road, Woburn, Massachusetts. The company was formed in June 2019, when CutisPharma, Inc. (itself founded in the late 1990s) acquired Silvergate Pharmaceuticals and adopted the Azurity name. It is private-equity backed; disclosed investors include NovaQuest Capital Management, QHP Capital and Schroders Capital. There is no public ticker, and the company does not publish financials. Third-party databases estimate roughly 500–1,000 employees, but headcount and revenue figures vary widely across those sources and are unaudited — I could not verify either from a primary filing.
Products / operations. Azurity develops and commercializes alternative dosage forms — chiefly ready-to-use oral liquids — of established medicines for patients who cannot swallow tablets or capsules (children, elderly, dysphagia). The company states it has 50+ medicines across 10 therapeutic areas in more than 50 countries, spanning cardiovascular, CNS/neurology, endocrinology, gastrointestinal, oncology supportive care and institutional markets. Named products from its own press releases include Xatmep (methotrexate oral solution), Nymalize (nimodipine oral solution), Firvanq (vancomycin oral solution), Eprontia (topiramate oral solution), Konvomep, Zonisade, Fleqsuvy, Brynovin (sitagliptin oral solution), Javadin (clonidine oral solution), Danziten (nilotinib tablets), Azmiro (testosterone cypionate injection), Ferabright (ferumoxytol injection) and Arynta (lisdexamfetamine oral solution). The portfolio was largely assembled by acquisition: Arbor Pharmaceuticals (2021), Slayback Pharma (2023), Covis Pharma (2025), Sebela's bowel-prep franchise (2025) and Contrave assets (2026).
Patent-litigation posture. In the tracked data Azurity appears as plaintiff/petitioner in all 4 cases and as defendant in zero — the profile of an operating company, not an NPE or shell licensor. All four are U.S. Patent and Trademark Office / PTAB filings dated 2025-05-01 against a single patent owner, Helsinn Healthcare S.A., in which Azurity is the petitioner. There is no NPE-defense pattern and no district court matter in the dataset.
Notable cases / context. The tracked PTAB filings correspond to the inter partes reviews Azurity filed against Helsinn's Orange Book-listed AKYNZEO (netupitant/palonosetron) chemotherapy-induced nausea and vomiting patents (U.S. 8,623,826; 9,186,357; 9,943,515; 10,828,297). Context: Azurity holds a tentative FDA approval for an aprepitant injectable emulsion (2024), and its Slayback subsidiary has filed netupitant/palonosetron formulation applications. Helsinn requested discretionary denial; the Director declined on September 19, 2025, and the Board instituted review on some petitions. Azurity has also filed PTAB petitions against Heron Therapeutics and Exelixis patents.
Watchlist
Email-only, free, anonymous. We'll notify you when Azurity Pharmaceuticals, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Azurity filed an inter partes review petition challenging U.S. 10,828,297 B2, owned by Helsinn, on obviousness grounds. The Board instituted trial on November 19, 2025, and the proceeding remains pending.
Inter partes review petition filed by Azurity Pharmaceuticals against Helsinn Healthcare challenging U.S. Patent No. 9,943,515. The Board instituted review on November 19, 2025, and the proceeding remains pending.
Inter partes review petition filed by Azurity Pharmaceuticals against Helsinn Healthcare challenging U.S. 9,186,357 B2. The proceeding is pending/instituted, with preliminary response and discretionary denial briefing.
Azurity Pharmaceuticals, Inc. filed a petition for inter partes review against Helsinn Healthcare S.A. challenging U.S. Patent No. 8,623,826 B2. The Board instituted review on November 19, 2025, and the proceeding remains pending.